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HUMAN Tg d lymphocytes constitute from 1 to 15% of
all  peripheral blood lymphocytes.  Recent work has
demonstrated that this population plays a major role
in  the  pathogenesis  of  infectious  and  immune  dis-
eases.  Increased  numbers  of  g d T  cells  have  been
found in  affected  skin  from  systemic  sclerosis  and
chronic cutaneous lupus erythematosus patients.
In our study, we have determined the numbers of
Tg d lymphocytes and their subpopulations in periph-
eral  blood  from  29  patients  with  systemic  lupus
erythematosus  (SLE)  and  in  19  healthy  volunteers
using flow cytometry  and specific  monoclonal anti-
bodies. The same cells in uninvolved skin from SLE
patients  and  human  controls  using  immunohisto-
chemical  analysis  were  estimated.  T-Cell  receptor
(TCR) delta chain gene rearrangement was identified
with primers for Vd 1, Vd 2 and Vd 3 by the polymerase
chain  reaction.  Statistical  analysis  showed  a  sig-
nificantly  decreased  number  of  g d T  cells  in  SLE
patients (26.4 ±  16.9/m l) compared with the control
group (55.3 ±  20.6/m l) (p < 0.001). The number of Vd 2
TCR+ and Vg 9 TCR+ subpopulations was also lower in
SLE patients  than  in  healthy  persons. No  statistical
correlation between disease activity and the number
of g d T cells was demonstrated. The percentage of Tg d
lymphocytes  in  clinically  normal  skin  from  SLE
patients was twice (22.0 ±  9.4%) that found in the skin
from  healthy  persons  (11.1  ±   5.5%)  (p <  0.002).
Higher  percentages  of the  Vd 2  TCR+ and Vg 9 TCR+
subpopulation of lymphocytes were found in the skin
from  SLE  patients.  We  have  also  found  positive
correlation between the percentage of Tg d lympho-
cytes  in skin and the activity  of SLE (r = 0.594, p <
0.001),  and  between  subpopulation  Vd 3  TCR+  and
disease activity (r = 0.659, p < 0.001). In conclusion,
the results of our studies demonstrate that, in patients
with  SLE, accumulation  of Tg d lymphocytes  can  be
seen in clinically normal skin, and the percentage of
these cells correlates with the activity of the disease.
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Introduction
Systemic  lupus  erythematosus  (SLE)  is  a  chronic
relapsing  autoimmune  disorder  of  unknown  origin
with many different clinical manifestations. SLE can
present with a wide range of immunological abnor-
malities,  such  as  the  production  of  a  variety  of
autoantibodies by activated B cells, the presence of
circulating  immune  complexes  and  a  reduction  in
complement levels.1,2 T cells may have an important
role in inducing B-cell hyperactivity.3,4 T cells in SLE
show  multiple  abnormalities  that include  the  pres-
ence  of  anti-T-lymphocyte antibodies, CD4 epitome
deficiency, low levels of interleukin-2 (IL-2) receptor
expression and increased levels  of soluble forms of
the  IL-2  receptor.5 The  most  common  changes  in
peripheral  blood  mononuclear  cell  subsets  are  a
reduction of CD4+ T cells and an increase of CD8+
cells with imbalance of the CD4/CD8 ratio.6
Most mature human T cells express T-cell receptors
(TCRs)  on  the  membrane  in  association  with  the
signal transduction CD3 complex. These cells are the
central  lymphocytes  in  the  immune  system. They
provide specific pathogen recognition and long-term
memory,  all  within  the  context  of  distinguishing
foreign  antigens  from  self-antigens7,8 Another  CD3-
associated  TCR  complex  is  composed  of  g -  and
d -polypeptides (TCRg d ), which has been identified in
a small population of double-negative (CD4–/CD8–) or
dimly CD8+ peripheral blood lymphocytes, tumor cell
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molecules consist of disulfide-linked or non-disulfide-
linked heterodimer depending on the use of Cg 2 or
Cg 1  segment-derived  TCRg chains,  respectively12
TCRg d cells rearrange and  express  clonally  diverse
antigen receptors similarly to TCRa b cells.13 Human
g d T cells range from 1 to 15% of peripheral blood
lymphocytes and show a predilection for the red pulp
of the spleen and gastrointestinal tract.14,15 Increased
levels of  g d T cells were detected in  damaged skin
from patients with infections and immune diseases,
such  as  leprosy,16 cutaneous  leishmaniases,17 sys-
temic sclerosis,18 and chronic cutaneous lupus  ery-
thematosus.19 Clonal expansion of TCRg d T cells has
also been reported in the peripheral blood of patients
with SLE.20 In contrast, we and other workers have
shown  that  the  absolute  number  of  g d T  cells  in
peripheral blood was lower in SLE patients than in
healthy controls.21,22
The pathologic relevance of g d T cells in autoim-
mune  diseases  is  suggested  by  their  reactivity  to
highly conserved stress proteins and by the accumu-
lation of these cells in affected organs.17,23,24 There
are  also  suggestions  that  g d T  cells  participate  in
both the regulation and the propagation of systemic
autoimmunity.25
In the present study, we have measured the number
of TCRg d cells and their subpopulations in peripheral
blood and in clinically normal skin of SLE patients. We
have also correlated the number of g d T cells with
disease activity.
Patients and methods
Clinical findings
The study involved 29 patients (27 females and two
males),  aged  18–66  years  (mean,  42  years).  The
diagnosis of SLE was based on the revised criteria of
the American Rheumatism Association (now known as
the American College of Rheumatology).26 The mean
duration  of  the  disease  was  72  months  (range,  1
month-11 years). Twenty-two patients had never been
treated with steroids or any other immunosuppressive
agents. Six patients were treated with prednisone at a
dose of 5–20mg/day during the study and one patient
with prednisone and azatioprine.
Patients  with  both  active  and  inactive  disease
were  included  in  the  study.  In  all  patients,  the
activity of the disease was determined according to
the systemic lupus activity measure (SLAM) scale, as
described by Linker-Israeli et al.3 This scale lists 32
clinical  and  laboratory  manifestations  of  SLE.  The
maximum score in this system is 84 points. In  our
group of patients, the number of points ranged from
9  to  25.  In  the  present  study,  we  considered  the
score  of  0–15  points  for  inactive  disease  and  the
score of  over  15  points  for  active  disease.  By  this
definition,  active  disease  was  found  in  15  patients
while 14  patients had inactive disease.
The clinical and laboratory features of SLE patients
are  presented  in  Table  1.  The  control  group  for
peripheral blood investigation comprised 19 healthy
volunteers (17 women and two men), aged from 35 to
58 years (median, 45 years). Each person underwent
a thorough physical evaluation by one of the authors
(E.R.). Samples of normal skin were excised from 10
individuals during an operation performed because of
trauma. Skin samples from the patients and control
group were collected from a clinically  normal, sun-
exposed area.
The  patients  with  SLE  and  controls  showed  no
clinical signs of an infectious or neoplastic disease and
were not given antibiotics or any other antibacterial
or antiviral medication for at least 4 weeks before skin
or blood donation. Informed consent was obtained
from all patients and normal individuals participating
in the study, which was approved by the local ethics
committee.
Blood samples and immunophenotype analysis
Venous blood samples obtained from all patients and
control individuals were collected at the time of clinical
assessment in pyrogen-free tubes containing anticoagu-
lant (ethylenediamine tetraacetic acid at a final concen-
tration  of  25nM).  Lymphocyte immunophenotyping
and TCR diversity analysis was performed by  EPICS
flow cytometer S-XL (Coulter, Hialaeah, FL, USA) and
standard  two-color  immunofluorescence  measure-
ment.  The details of the procedure have been described
in our previous studies.21,27,28 Briefly, a combination of
phycoerythrin-conjugated and fluorescein isothiocya-
nate-conjugated monoclonal antibodies (MoAbs) was
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Table 1. Clinical and laboratory characteristics of the patients
with SLE
Symptoms Number
of patients
%
Total 29 100.0
Active 15 51.7
Inactive 14 48.3
Fever 6 20.7
Arthritis 24 82.7
Skin symptoms 14 48.3
Cardiovascular symptoms 6 20.7
Neurologic symptoms 24 82.8
Antinuclear antibodies 26 89.7
Immunoglobulin deposits at the
dermal–epidermal junction
15 51.7
Anemia (hemaglobin <12g/dl) 10 34.5
Leukopenia (white blood cells
<3.5 ´ 10
9/l)
10 34.5
Thrombocytopenia (<150 ´ 10
9/l) 8 27.6
Raised ESR* (>25mm/h) 24 82.8
Treatment with steroids during the study 6 200.7
Treatment with steroids and cytotoxic
agents during the study
1 3.5
*ESR, erythrocyte sedimentation rate.used. In polystyrene tubes, 100 m l samples of whole
blood were directly stained with 10 m l of appropriate
MoAbs in the dark, at room temperature. Immunoglo-
bulin  (Ig)  G1 isotype  control  antibody  conjugates
were  included to  establish the background fluores-
cence. After incubation for 30min, the samples were
placed to Q-prep (Coulter)  for lysis of erythrocytes
and fixation of nuclear cells. At least 10,000 cells were
then analyzed. Gate check was used to gate lympho-
cyte population defined by FS/SS and anti-CD14 and
CD45 RO MoAbs. Analysis was performed using XLv2
software.
Immunohistochemistry of skin biopsies
In SLE patients, biopsies from clinically normal skin
were taken from the wrist during routine diagnostic
procedure  of  Ig  deposit  examination.  Control  skin
samples were also collected from sun-exposed areas.
The samples were kept at –80°C. Frozen section was
carried out with a microtome (cryocut)  with 3 m m
layers each for histochemical study in the detection
system  LSAB  PLUS  PAP  (DAKO),  according  to  the
method described by  Hsu  et al.28 The examination
was carried out using monoclonal murine antibodies
DAKO  against  CD4,  CD3,  CD8  and  Immunotech
against pan TCRg d , Vd 2, Vd 3 and Vg 9. The presence or
absence  of  expression  of  a  particular  antigen  in
lymphoid T cells was evaluated in several randomly
chosen  visual  fields  of  a  given  preparation.  Using
Hogg’s grid, all cells in the infiltrate were calculated,
determining  the  percentage  of  cells  with  positive
reactions in relation to all cells of the infiltrate in the
examined visual fields.
The results were expressed as percentages.  Through-
out the whole period of study, pathologists were not
informed about the source of tissue samples.
Analysis of TCR gene rearrangements by
polymerase chain reaction
Frozen slices of skin specimens from studied patients
were used for DNA isolation by routine proteinase K
digestion  and  the  phenol–chloform  extraction
procedure.29
The  multiplex  polymerase  chain  reaction  (PCR)
procedure for the identification of TCRd chain gene
rearrangement described by  Sambrook et al.30 was
used to identify the repertoire of TCRg d expressed on
T  lymphocytes  in  skin  specimens.  Three  pairs  of
primers were used together:
Forward primers:
Vd 1: 59 -ACTCAAGCCCAGTCATCAGTATCC-39
Vd 2: 59 -ACCAAACAGTGCCTGTGTCAATAGG-39
Vd 3: 59 -TGAGGTGGTACTGCTCTGCACTTACG-39
Reverse primer:
Jd 1: 59 -ACCTCTTCCCAGGAGTCCTCC-39
Briefly, the genomic DNA was amplified in 20 m l of 1
´ PCR  buffer  containing  200m mol  of  each  dNTP,
3pmol of each primer and 1U of Taq polymerase. The
amounts  of  rearranged  DNA  obtained  from  the
analyzed samples (especially from normal skin infil-
trating lymphocytes) were low. In that case, the PCR
reaction was performed with a -32P-dCTP (370MBq/
ml) to improve the sensitivity of amplification (0.25 m l
per tube). Thirty cycles were run on a thermocycler
(Perkin Elmer 2400) under the following conditions:
denaturation at  94°C  for  1min  (10min  in  the  first
cycle), annealing at 64°C for 1min, extension at 72°C
for 1.5min (7min in the last cycle). The radioisotope-
labeled  PCR  sample  products  were  resolved  using
horizontal 3% agarose gel  electrophoresis. Then gel
was  vacuum-dried  and  the  reaction  products  were
visualized by autoradiography. The intensity of bands
(with sizes for different rearrangements between 200
and  400  base  pairs)  was  analyzed  with  Molecular
Analyst  software  using  the  Gel  Doc  1000  Bio-Rad
system.  The  relative  proportions  of  different  Vd
lymphocyte subsets were calculated.
Statistical analysis
To statistically calculate the obtained data the range of
measured variables has been given (min–max), and
mean arithmetic values (x) and standard deviation (SD)
were calculated.  The type of distribution of the studied
features was evaluated with the Shapiro–Will test. The
comparison of values of type variables in two groups
were  performed  depending  on  the  distribution  of
features with the Mann–Whitney test or a test for two
means from small samples (in this case, the condition
of homoscedasticity was checked by the Fischer test).
If  the  condition  of  homoscedasticity was  not  met,
comparison  between  mean  values  was  carried  out
with the Cochran–Cox test. The differences in mean
values  in  three  groups  were  evaluated  with  the
Kruskal–Wallis test or by the analysis of variance.  Then,
the  Mann–Whitney  test  or  Tukey  test  performed
indirect  comparisons. The  correlation  between  fea-
tures was evaluated by straight-line correlation coeffi-
cient (r) or by Spearman rank coefficient.
Results
In the present study, we have evaluated the number of
Tg d cells and their subpopulations in the peripheral
blood  and  in  normal  skin  of  29  SLE  patients. The
characteristics of the studied patients are presented in
Table 1. The control group comprised of 19 healthy
sex-  and  age-matched  volunteers,  and  10  patients
undergoing cosmetic surgery procedures.
The expression of TCR on peripheral blood lympho-
cytes and also the number of CD3+, CD4+ and CD8+
lymphocytes  were  calculated  by  standard,  double
color immunofluorescence measurement. The results
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nificantly lower number of g d T cells in SLE patients
(26.4  ±  16.9/m l)  than  in  healthy  persons  (55.3  ±
20.6/m l)  (p <  0.001).  However,  no  statistically  sig-
nificant  correlation  between  the  concentration  of
these  cells  and  clinical  activity  of  the  disease  was
found (p > 0.05) (Fig. 1). Among three g d T subpopula-
tions, only the concentration of Vd 3 TCR+ was over
twice higher in SLE (4.8 ± 6.8)  patients, compared
with the control group (2.2 ± 3.1), both in the active
(5.0 ± 8.4) and inactive stage of the disease (4.5 ±
4.8), but the difference was not significant statistically
(p > 0.05). The concentration of other g d T subpopula-
tions and CD3+, CD4+ and CD8+ cells was statistically
significantly lower in the patients with SLE than in the
control group (Table 2). Tg d lymphocytes in clinically
normal skin of SLE patients and control patients were
evaluated by the immunohistochemical method. TCR
gene rearrangement analysis was carried out by the
PCR method (Fig. 2). The accumulation of particular
T-lymphocyte  subpopulations  in  the  skin  of  SLE
patients and in healthy persons is presented in Table
3. In SLE patients, the percentage of Tg d lymphocytes
in the skin was twice higher (22.0 ± 9.5%) than in the
skin of healthy persons (11.1 ± 5.5%) (p < 0.002). A
higher  percentage of  these  cells  was also  noted in
patients with active disease (27.0 ± 9.4%) than in non-
active SLE (16.6 ± 5.6%) (p < 0.002). Similar differ-
ences were noted in the percentage of Vd 2 TCR+ and
Vg 9 TCR+ subpopulations in SLE patients and in the
skin  of  healthy  persons  (Table  3).  However,  the
differences in the percentage of Vd 3 TCR+ subpopula-
tions  were  not  statistically  significant.  Similarly,  a
higher  percentage  of  this  subpopulation  was
observed in  patients with active SLE  (10.5  ± 4.8%)
than in patients with non-active SLE (6.8 ± 3.5%; p <
0.03) and in healthy persons (3.6 ± 3.1%, p < 0.02). It
should  also  be  pointed  out  that the  percentage of
E. Robak et al.
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Table 2. Analysis of g d TCR expression on peripheral blood T cells in patients with SLE and healthy donors (cell donors/m l)
Cell
subpopulation
SLE (n = 29)
Total
(n = 29)
(a)
Active
(n = 15)
(b)
Inactive
(n = 14)
(c)
Control
(n = 19)
(d) Comparison p value
Pan g d TCR
+ (a)–(d) <0.001*
Mean ± SD 26.4 ± 16.9 25.7 ± 14.6 27.3 ± 19.7 55.3 ± 20.6 (b)–(c)–(d) <0.001*
Median 27.0 27.09 23.765 50.0 (b)–(c) >0.05
Range (2.0–68.8) (8.0–68.8) (2.0–59.4) (20.0–90.0) (b)–(d) <0.001*
(c)–(d) <0.001*
Vd 2 TCR
+ (a)–(d) <0.001*
Mean ± SD 14.2 ± 12.6 16.5 ± 12.7 11.7 ± 12.4 38.1 ± 23.6 (b)–(c)–(d) <0.001*
Median 12.5 12.88 9.225 30.0 (b)–(c) >0.05
Range (0.0–53.7) (0.0–53.7) (1.1–49.3) (4.0–70.0) (b)–(d) <0.002*
(c)–(d) <0.001*
Vd 3 TCR
+ (a)–(d) >0.05
Mean ± SD 4.8 ± 6.8 5.0 ± 8.4 4.5 ± 4.8 2.2 ± 3.1 (b)–(c)–(d) >0.05
Median 2.24 1.40 2.905 0.20 (b)–(c) >0.05
Range (0.0–25.0) (0.0–25.0) (0.0–17.4) (0.08–9.0) (b)–(d) >0.05
(c)–(d) >0.05
Vg 9 TCR
+ (a)–(d) <0.002*
Mean ± SD 16.5 ± 13.5 16.7 ± 12.0 16.2 ± 15.4 41.3 ± 31.1 (b)–(c)–(d) <0.005*
Median 13.86 13.86 13.65 30.0 (b)–(c) >0.05
Range (0.0–57.1) (0.0–49.8) (1.1–57.1) (4.0–100.0) (b)–(d) <0.01*
(c)–(d) <0.004*
CD3
+ (a)–(d) <0.001*
Mean ± SD 737.9 ± 485.1 897.85 ± 419.0 566.6 ± 506.6 1174.9 ± 336.7 (b)–(c)–(d) <0.001*
Median 775.0 872.16 486.445 1201.0 (b)–(c) >0.05
Range (12.0–1782.5) (376.1–1782.5) (12.0–1741.7) (510.0–1770.0) (b)–(d) <0.02*
(c)–(d) <0.001*
CD4
+ (a)–(d) <0.001*
Mean ± SD 203.4 ± 188.3 267.5 ± 215.7 134.6 ± 128.2 471.2 ± 185.2 (b)–(c)–(d) <0.001*
Median 148.12 161.0 111.86 518.0 (b)–(c) >0.05
Range (6.0–723.0) (44.0–723.0) (6.0–449.1) (197.0–891.0) (b)–(d) <0.008*
(c)–(d) <0.001*
CD8
+ (a)–(d) <0.001*
Mean ± SD 281.8 ± 214.0 340.5 ± 215.0 218.9 ± 201.6 451.7 ± 118.9 (b)–(c)–(d) <0.001*
Median 232.0 256.68 199.43 430.0 (b)–(c) >0.05
Range (4.0–815.0) (114.5–815.0) (4.0–619.1) (271.0–632.0) (b)–(d) <0.005*
(c)–(d) <0.001*
*Statistically significant difference.CD3+ lymphocytes  in  the  skin of  SLE  patients  and
healthy persons was similar (81.4  ± 7.9 and 83.0 ±
13.4%, respectively; p > 0.05). We have also found a
positive correlation between the percentage of Tg d
lymphocytes in the skin and the activity of the disease
(r =  0.594,  p<  0.001)  and  between  the Vd 3 TCR+
subpopulation and the activity of SLE (r = 0.659, p <
0.001)  (Fig.  3). The correlation between infiltration
with Tg d lymphocytes and their subpopulations in the
skin of SLE patients and the number of these cells in
peripheral  blood  was  also  evaluated.  A  negative
correlation between these parameters was noted, but
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FIG. 1. Correlation between the number of g d T cells and their subpopulations in peripheral blood with SLE activity score. The
disease  activity  was  determined  according  to  the  SLAM  scale  as  described  by  Linker-Israeli  et  al.
3 Lymphocyte
immunophenotyping analysis was performed by the direct staining of cells with commercially prepared MoAbs and standard
two-color  immunofluorescence  measurement  using  EPICS  flow  cytometer  S-XL.  The  correlation  between  features  was
evaluated by Spearman rank coefficient. No statistically significant correlation between the concentration of investigated cells
and clinical activity of SLE was found (p > 0.05).E. Robak et al.
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FIG. 2. Resolution of multiplex PCR products for the identification of TCRd gene rearrangements. Electrophoresis in 3% agarose
gel and autoradiography were performed. Lanes 1–8, control skin specimens; lanes 9–14, unevolved skin specimens of SLE
patients; lane B, peripheral blood sample from healthy donor.
Table 3. Accumulation of g d T cells in normal skin from SLE patients and normal controls (percentage of cells with positive
reactions relative to all cells of the infiltrate in the examined visual fields)
Cell
subpopulation
SLE (n = 29)
Total
(n = 29)
(a)
Active
(n = 15)
(b)
Inactive
(n = 14)
(c)
Control
(n = 10)
(d) Comparison p value
Pan g d TCR
+ (a)–(d) <0.002*
Mean ± SD 22.0 ± 9.4 27.0 ± 9.4 16.6 ± 5.6 11.1 ± 5.5 (b)–(c)–(d) <0.02*
Median 20.0 26.0 16.5 11.5 (b)–(c) <0.002*
Range (7.0–50.0) (11.0–50.0) (7.0–29.0) (4.0–20.0) (b)–(d) <0.001*
(c)–(d) <0.03*
Vd 2 TCR
+ (a)–(d) <0.002*
Mean ± SD 8.9 ± 4.5 10.5 ± 4.8 6.8 ± 3.5 3.6 ± 3.1 (b)–(c)–(d) <0.002*
Median 8.0 10.0 6.5 2.5 (b)–(c) <0.03*
Range (2.0–18.0) (2.0–18.0) (2.0–15.0) (1.0–10.0) (b)–(d) <0.002*
(c)–(d) <0.02*
Vd 3 TCR
+ (a)–(d) >0.05
Mean ± SD 8.0 ± 4.5 10.1 ± 4.8 5.7 ± 3.0 5.1 ± 2.5 (b)–(c)–(d) <0.003*
Median 7.0 11.0 6.0 4.5 (b)–(c) <0.008*
Range (1.0–20.0) (3.0–20.0) (1.0–11.0) (2.0–10.0) (b)–(d) <0.007*
(c)–(d) >0.05
Vg 9 TCR
+ (a)–(d) <0.003*
Mean ± SD 7.3 ± 4.6 7.9 ± 5.0 6.7 ± 4.4 2.6 ± 2.3 (b)–(c)–(d) <0.008*
Median 6.0 7.0 6.0 1.5 (b)–(c) >0.05
Range (1.0–19.0) (1.0–19.0) (1.0–16.0) (1.0–7.0) (b)–(d) <0.004*
(c)–(d) <0.02*
CD3
+ (a)–(d) >0.05
Mean ± SD 81.4 ± 7.9 82.3 ± 7.3 80.4 ± 8.7 83.0 ± 13.4 (b)–(c)–(d) >0.05
Median 85.0 85.0 82.5 90.0 (b)–(c) >0.05
Range (70.0–95.0) (70.0–95.0) (70.0–95.0) (50.0–95.0) (b)–(d) >0.05
(c)–(d) >0.05
CD4
+ (a)–(d) <0.001*
Mean ± SD 45.0 ± 8.3 46.3 ± 9.3 43.6 ± 7.2 57.0 ± 5.4 (b)–(c)–(d) <0.002*
Median 45.0 45.0 40.0 57.5 (b)–(c) >0.05
Range (30.0–60.0) (35.0–60.0) (30.0–55.0) (45.0–65.0) (b)–(d) <0.02*
(c)–(d) <0.001*
CD8
+ (a)–(d) <0.001*
Mean ± SD 55.0 ± 8.3 53.7 ± 9.2 56.4 ± 7.2 43.0 ± 5.4 (b)–(c)–(d) <0.002*
Median 55.0 55.0 60.0 42.5 (b)–(c) >0.05
Range (40.0–70.0) (40.0–65.0) (45.0–70.0) (35.0–55.0) (b)–(d) <0.02*
(c)–(d) <0.001*
*Statistically significant difference.the differences were not statistically significant (p >
0.05) (Fig. 4).
In the analyzed group of 29 SLE patients, six were
treated with prednisone during the study. All of them
were with inactive disease.  The influence of treatment
with prednisone on the number g d T cells in periph-
eral blood and their percentage in clinically normal
skin is presented in Table 4.
The percentage of Tg d cells in clinically normal skin
was  lower  in  the  patients  with  SLE  treated  with
prednisone (mean, 15.3  ± 5.2) than in the patients
who were not treated with this agent (mean, 23.7 ±
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FIG. 3. Correlation between the percentage of pan g d T cells and their subpopulations determined by the immunohistochemical
method in clinically normal skin and SLE activity score. The examination was performed using murine MoAbs against TCRg d ,
Vd 2, Vd 3, and Vg 9. Estimation of the percentage of the cells with positive reactions in relation to all the cells in the infiltrate was
evaluated. Hogg’s grid in the examined visual fields was used. The correlation was evaluated by straight-line correlation
coefficient (r) or by Spearman rank coefficient. Positive correlation between the percentage of the Tg d lymphocytes as well as
the Vd 3 TCR+ subpopulation and SLE activity was found.9.5) (p < 0.04). Similarly, the percentage of Vd T CR+
subpopulation was lower in patients who were not
treated with prednisone (mean, 5.5 ± 2.7%) than in
the treated patients (mean, 9.5 ± 4.6%).
The  results  of  the  identification  of  TCRd gene
rearrangements by the PCR method and evaluation of
amplified product density on gel are presented in Fig.
2 and in Table 4. It is difficult to compare, on the basis
of molecular assays, the number of Tg d cells infiltrat-
ing  skin specimens. Our  semiquantitative  estimates
suggest that the total number of Tg d cells vary in the
range of error between samples from SLE patients and
healthy individuals (data not shown). However,  we
observed the appearance of the Vd 3+ T-cell subset in
T-lymphocyte  population  infiltrating  the  skin  speci-
mens  from  SLE  patients  (22.4  ±  9.4%  for  the total
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FIG. 4. Correlation between the number of g d T cells and their subpopulations in peripheral blood and the percentage of these
cells in clinically normal skin of SLE patients. The correlation between features was evaluated by Spearman rank coefficient.
Negative correlation between investigated parameters was noted, but the differences were not statistically significant.group). Practically, this subpopulation was not found
in skin samples from healthy control patients (1.4 ±
1.9%). We noted a significant relative decrease in the
Vd 2+ T-cell subset in skin specimens of SLE patients.
The relative proportion of the Vd 1+T-cell subpopula-
tion  was  not  significantly  changed. The Vd 2+ T-cell
subpopulation dominates in the blood from healthy
donors  (more  than  80%  of  pan  T  lymphocytes),
confirming the results of earlier studies.21 The diffuse
electrophoretic bands of PCR-amplified d TCR genes
revealed their extensive junctional diversity. This may
reflect the polyclonal T-cell response to a diverse array
of recognizable antigens.
Discussion
The aim of  the  present study  was to quantitatively
evaluate the number of Tg d lymphocytes in peripheral
blood and clinically healthy skin of SLE patients and to
compare these results with their respective values in
healthy individuals. The number of Tg d lymphocytes in
peripheral blood of SLE patients was found to be much
smaller than in healthy persons, irrespective of SLE
disease activity. Similar differences were observed for
subpopulations Vd 2 TCR+, Vg 9 TCR+, CD3+, CD4+,
and  CD8+.  However,  mean  values  of  Vd 3  TDR+
lymphocytes  were  twice  as  high  in  SLE  patients
compared with the control group. These differences
did  not  correlate  with  the  activity  of  disease. The
number of Tg d lymphocytes in peripheral blood of SLE
patients was also lower than in healthy persons, even
though the majority of patients in the present study
had not been treated with corticosteroids or other
immunosuppressive  drugs.  In  the  previous  study
group, 22 patients among 32 (68.7%) received corti-
costeroids.  We cannot therefore exclude the possibility
that  the  administration  of  corticosteroids does  not
affect significantly the level of Tg d lymphocytes and
Vd 2  TCR+ subpopulation  in  peripheral  blood.21 A
similar study was conducted by Lunardi et al.31 in a
group of 35 SLE patients and 36 healthy persons. They
found almost a 50% reduction in the percentage of Tg d
lymphocytes in the blood of SLE patients compared
with the control group. However, similar to our study,
no correlation was found between the number of these
cells and the activity of SLE.
Determination of  the percentage of  g d T lympho-
cytes  and  their subpopulations  in  clinically  healthy
Lymphocytes Tg d in SLE
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Table 4. g d T cells in peripheral blood and accumulation of g d T cells in clinically normal skin from SLE patients treated and not
treated with prednisone during the study
Cell
subpopulation
Cells in peripheral blood/m l
Prednisone (+)
(n = 6)
Prednisone (–)
(n = 23) p value
Percentage of cells with positive reaction
relative to all cells
Prednisone (+)
(n = 6)
Prednisone (–)
(n = 23) p value
Pan g d TCR
+
Mean ± SD 20.8 ± 13.5 27.9 ± 17.7 15.3 ± 5.2 23.7 ± 9.5
Median 23.765 27.09 >0.05 15.2 24.0 <0.04*
Range (3.4–39.0) (2.0–68.8) (9.0–24.0) (7.0–50.0)
Vd 2 TCR
+
Mean ± SD 6.5 ± 5.7 16.3 ± 13.2 5.5 ± 2.7 9.5 ± 4.6
Median 4.225 12.88 >0.05 6.0 9.0 <0.05*
Range (1.1–14.0) (0.0–53.7) (2.0–9.0) (2.0–18.0)
Vd 3 TCR
+
Mean ± SD 2.5 ± 2.4 5.4 ± 7.5 6.2 ± 3.4 8.4 ± 4.7
Median 1.665 2.31 >0.05 5.5 7.0 >0.05
Range (0.0–6.8) (0.0–25.0) (2.0–11.0) (1.0–20.0)
Vg 9 TCR
+
Mean ± SD 8.9 ± 7.2 18.5 ± 14.1 5.5 ± 3.9 7.8 ± 4.8
Median 7.645 17.94 >0.05 5.0 6.0 >0.05
Range (1.1–18.0) (0.0–57.1) (1.0–11.0) (1.0–19.0)
CD3
+
Mean ± SD 563.2 ± 432.6 783.5 ± 496.4 79.2 ± 10.2 82.0 ± 7.3
Median 617.75 775.0 >0.05 77.5 85.0 >0.05
Range (20.1–1044.1) (12.0–1782.5) (70.0–90.0) (70.0–95.0)
CD4
+
Mean ± SD 124.5 ± 86.7 223.9 ± 203.2 42.5 ± 8.2 45.7 ± 8.4
Median 122.35 148.12 >0.05 42.5 45.0 >0.05
Range (10.1–235.4) (6.0–723.0) (30.0–55.0) (35.0–60.0)
CD8
+
Mean ± SD 218.4 ± 218.4 298.4 ± 214.7 57.5 ± 8.2 54.3 ± 8.4
Median 189.3 232.0 >0.05 57.5 55.0 >0.05
Range (6.7–605.7) (4.0–815.0) (45.0–70.0) (40.0–65.0)
*Statistically significant difference.skin in SLE patients revealed very interesting results.
Immunohistochemical studies revealed that the per-
centage of Tg d lymphocytes and their subpopulations
Vd 2TCR+ and Vg 9TCR+ is significantly higher in SLE
patients  than  in  healthy  persons,  and  is  higher  in
patients with active SLE than with inactive disease.
Similar results were seen for all three subpopulations.
We have also found a positive correlation between the
activity of SLE and the percentage of Tg d lymphocytes
(r = 0.594, p < 0.001) and Vd 3 TCR+ lymphocytes (r
= 0.659, p < 0.001). Our results were also confirmed
by  molecular analysis. The presence of lymphocyte
populations with gene rearrangements characteristic
for Vd 3+ cells in  the skin of SLE patients has been
confirmed beyond doubt (Fig. 2 and Table 5). If these
data are compared with the results of the immunohis-
tochemical test, it should be kept in mind that the
percentage  of  cells  with  Vd 3+ rearrangement  was
determined in relation to the sum of amplified PCR
product and may  not  be  applied  for  the  particular
number of skin cells. Moreover, mature and selected
lymphocytes  with  a  particular  rearrangement  type
may not have such a TCRd gene on the membrane
surface.  It  has  been  demonstrated  that  effective
rearrangement of the TCRd gene is not solely limited
to Td g lymphocytes, but may also be present in the
genome  of  cellular  clones  presenting  receptor
TCRa b .32 In  addition,  the  phenomenon  of  ‘allelic
exclusion’  in  the  case  of Tg d lymphocytes  is  not
always present,33 and the process of negative selec-
tion of these cells most probably occurs in peripheral
target  tissues.34 Our  results  also  suggest  that these
cells may play a role in the pathogensis of SLE and that
the  determination  of Tg d lymphocytes  in  clinically
healthy skin may have prognostic value.
Tg d lymphocytes in the skin have been previously
determined  in  other  autoimmune  diseases.  Volc-
Platzer et al.19 found the accumulation of these cells
in  pathologically  changed  skin  of  patients  with
chronic cutaneous lupus erythematosus. They claim
that Tg d lymphocytes, due to their cytotoxic proper-
ties, may  be  responsible for epithelial damage. Tg d
lymphocytes  have  also  been  evaluated  in  patients
with systemic sclerosis, similar to our study, where
the  percentage  of  these  cells  in  systemic  sclerosis
patients was found to be higher than in the control
group.18 Similar  observations  were  made  in  some
infectious  skin diseases such as leprosy16 and cuta-
neous  leishmaniasis.17 However,  like  the  published
studies  of  systemic  sclerosis  and  cutaneous  lupus
erythematosus patients, accumulation of Tg d lympho-
cytes was studied in pathologically changed skin but
not in  clinically  healthy skin, like in  our  study. We
believe that our study is the first to demonstrate that,
in  an  autoimmune  disease  like  SLE,  these  cells
accumulate  in  clinically  healthy  skin  as  well  as  in
diseased skin. The differences in the number of T cells
between  the  blood  and  tissues  may  suggest  their
migration from blood to skin in SLE patients, mainly
during exacerbation of disease.
In  the  present  study,  we  have  shown  lower
percentage of lymphocytes Tg d and their Vd 2 TCR+
subpopulation  in  the  skin  of  patients  treated  with
prednisone than in the patients who were not treated
with this agent during the study. It has been shown
earlier that long-continued immunosuppressive ther-
apy determined the disappearance of expanded g d T
cells in target tissues of patients with polymyositis or
other autoimmune  diseases.35,36 The  in  vitro study
indicated that all T lymphocytes bearing the g d TCR
isolated  from  SLE  patients  and  healthy  individuals
were  susceptible  to  dexamethasone,  and  steroid-
induced apoptosis was the basic mechanism responsi-
ble for cell death.37 The same study has shown that
6-month glucocorticoid treatment normalized SLE g d
T-cell subfraction in blood simultaneously with clin-
ical remission.
The mechanism that leads to the accumulation of
Tg d lymphocytes in SLE patients has not been fully
elucidated. Lymphocyte trafficking is thought to be due
to  surface  expression  of  three  different  families  of
cellular adhesion molecules (immunoglobulin  super-
family receptors, integrins and selectins).38This mecha-
nism may be supported by the fact that in SLE patients
there are deposits of immunoglobulins IgG or IgM, and
less commonly IgA in the dermo-epidermal junction.
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Table 5. The Vd 3 gene rearrangement in T cells infiltrating skin specimens of SLE patients and healthy controls (percentage of
Vd 3 amplified material in relation to total PCR product visible on the gel)
Characteristics
SLE (n = 29)
Total
(n = 29)
(a)
Active
(n = 15)
(b)
Inactive
(n = 14)
(c)
Control
(n = 8)
(d) Comparison p value
Vd 3 subpopulation (a)–(d) <0.001*
Mean ± SD 22.4 ± 9.4 25.7 ± 7.9 18.9 ± 10.8 1.4 ± 1.9 (b)–(c)–(d) <0.001*
Median 25.5 28.0 22.5 0.5 (b)–(c) <0.05*
Range (2.0–36.0) (8.0–33.0) (2.0–36.0) (0.0–4.5) (b)–(d) <0.001*
(c)–(d) <0.001*
*Statistically significant difference.In  conclusion,  it  has  been  confirmed  that  Tg d
lymphocytes accumulate in clinically healthy skin in
SLE patients, and that the percentage of these cells
correlates with the activity of the disease.
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